Michael Ackermann, CEO of a med-tech startup that created a tear-stimulation device for those with dry-eye disease, explains how acquisition by a global pharmaceutical giant is helping him achieve his goal of reaching as many patients as possible. Ackermann, a graduate of the Stanford Byers Center for Biodesign, also discusses why big tech companies have yet to disrupt healthcare and how that translates into big opportunities for entrepreneurs.
Related

Video
Innovation
Building Better Online Communities [Entire Talk]
Sarah Friar, Nextdoor
49 minutes

Video
Innovation
The Language of Technology [Entire Talk]
Ravi Mhatre, Lightspeed Venture Partners
45 minutes

Video
Innovation
Making a Difference in Biotech [Entire Talk]
George Scangos, Vir Biotechnology
44 minutes

Video
Innovation
Innovating for Equity [Entire Talk]
Adam Pisoni, Abl Schools
48 minutes